Biocon turns to margins and capacity use after heavy global expansion investments

Revenue rises 13 percent but profit drops sharply

Biocon says it is moving from an expansion phase to a focus on capacity utilization, margin expansion, and stronger returns. After major investments to build global capabilities, the company reported 13% revenue growth for FY26, but net profit fell significantly. Biocon is also aiming for sustainable profitable growth while exploring in-licensing for its biosimilars portfolio.